Tositumomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD20 |
| Clinical data | |
| Trade names | Bexxar |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a609013 |
| Identifiers | |
| CAS Number | 192391-48-3  |
| ATC code | V10XA53 (WHO) (sequential regimen with 131I form) |
| DrugBank | DB00081 |
| UNII | 0343IGH41U |
| KEGG | D08622 |
| ChEMBL | CHEMBL1201604  |
| Chemical data | |
| Formula | C6416H9874N1688O1987S44 |
| Molecular mass | 143859.7 g/mol |
| (what is this?) (verify) |
|
Tositumomab was a drug that was approved for the treatment of relapsed or chemotherapy/rituxan-refractory Non-Hodgkin lymphoma in 2003.[1] It was sold in the U.S. and Canada under the trade name Bexxar. Sale of the drug was discontinued and marketing approval was withdrawn in February 2014 due to the decline in usage (fewer than 75 patients in 2012) and the existence of other similar drugs.[2][3]
This drug combination was developed by Corixa which was purchased by GlaxoSmithKline) in 2005.[4]
References
- ↑ New York Times. July 1, 2003 Company News: Corixa and Glaxo's Cancer Drug Wins FDA Approval
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Notice by the Food and Drug Administration on October 23, 2013. GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With Relapsed or Refractory, Low Grade, Follicular, or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR
- ↑ Carla Mozee for MarketWatch. April 29, 2005 Glaxo to acquire Corixa for $300 million
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
